Ten Fraction Adjuvant Hypofractionated Radiotherapy in Node Positive Breast Cancer (HIPOMAMMLINF)

Regina Elena Cancer Institute

Status: Completed

Conditions: Breast Cancer

Treatments: Radiation: breast/chest wall radiotherapy

Study type: Observational

Funder types: Other

Identifiers

NCT04792346

RS618/14(1611)

Details and patient eligibility

About

Post-operative loco-regional (LR) hypofractionated radiotherapy (Hypo-RT) is an attractive approach in locally advanced breast cancer (LABC).

Full description

The present is a single arm phase II study assessing toxicity levels after 34 Gy/10 fxs/2 wks to the whole breast/chest wall and to the draining lymph nodes; an optional single fraction 8 Gy boost was administered with electrons to the tumor bed in patients who had undergone conservative surgery. Both acute (CTCAE v4.0) and late (LENT/SOMA) toxicity were collected. All pts but those who underwent mastectomy without reconstruction or with temporary expander were also asked to rate their cosmetic outcome according to the Harvard. Toxicity was assessed weekly during RT and then at each follow-up examination (1, 3, 6 months and then yearly).

Enrollment: 61 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients affected by invasive breast cancer who underwent conservative breast surgery or mastectomy and axillary dissection, followed by post operative radiotherapy at the level of the breast/chest wall, and of the supraclavicular, third axillary level +/- internal mammary chain nodes.
• pT1-3 disease pN1-2, cT1-3 disease if neoadjuvant chemotherapy , cN + cytologically and/or histologically assessed;
• ECOG Performance status ≤2;
• histologically negative surgical margins
• no distant metastases
• no prior chest radiotherapy
• life expectancy ≥ 5 years
• no prior cancer

Exclusion criteria

• Non-epithelial breast cancer (sarcoma, lymphoma etc.)
• Metastases at the level of the internal chain mammary and / or supra-clavicular lymph nodes histologically assessed
• pT4 neoplasms or inflammatory breast carcinoma
• Distant metastasis
• Concomitant chemotherapy
• history of prior controlateral breast tumor